文献速递炎症性肠病消化内镜消化道肿瘤与早癌

色素内镜在溃疡性结肠炎和克罗恩病监测中的应用:随机试验的系统综述

Chromoendoscopy for Surveillance in Ulcerative Colitis and Crohn's Disease: A Systematic Review of Randomized Trials.
PubMed 文献 · Clin Gastroenterol Hepatol · 2016-11-25

该系统综述纳入10项随机试验共1500例患者,比较色素内镜与其他内镜技术监测炎症性肠病异型增生的效果。色素内镜检出异型增生患者的可能性更高(RR 1.37,95%CI 1.04-1.79),但亚组分析仅在对比标准清晰度白光内镜时确认此效应(RR 2.12,95%CI 1.15-3.91),且操作时间显著延长(均值差8.91分钟,95%CI 1.37-16.45)。

要点

  • 色素内镜检出异型增生患者的可能性高于其他技术(RR 1.37,95%CI 1.04-1.79)。
  • 亚组分析仅对比标准清晰度白光内镜时确认效应(RR 2.12,95%CI 1.15-3.91)。
  • 色素内镜操作时间显著延长(均值差8.91分钟,95%CI 1.37-16.45)。

核心结论

  • 在炎症性肠病监测中,色素内镜仅在与标准清晰度白光内镜比较时检出更多异型增生患者,且操作时间更长,无直接证据表明对预防全因/癌症特异性死亡率或间期癌时间有影响。

研究设计与样本

  • 系统综述与随机试验的荟萃分析,检索MEDLINE、EMBASE和Cochrane对照试验中心注册库截至2016年9月发表的研究,纳入10项随机试验共1500例参与者。

主要发现

  • 色素内镜检出异型增生患者的可能性高于其他技术(RR 1.37;95%CI 1.04-1.79)。
  • 亚组分析仅在色素内镜对比标准清晰度白光内镜时确认该效应(RR 2.12;95%CI 1.15-3.91)。
  • 色素内镜操作时间显著长于其他技术(均值差8.91分钟;95%CI 1.37-16.45)。
  • 两组间检出异型增生亚型和靶向活检检出异型增生的可能性无差异,试验敏感性和特异性相似。

局限性

  • 无直接证据表明色素内镜对预防全因/癌症特异性死亡率或间期癌时间有影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Key international guideline agencies recommend dysplasia surveillance in inflammatory bowel diseases with chromoendoscopy. We performed a systematic review of randomized trials comparing chromoendoscopy vs other endoscopic techniques for dysplasia surveillance in inflammatory bowel diseases. METHODS: We searched MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials for relevant studies published through September 2016. We estimated risk ratios (RRs) for dichotomous outcomes (all-cause/colorectal cancer-related mortality, time to interval cancer, patients with dysplasia, total/subtypes of dysplastic lesions, dysplasia detected by targeted biopsies, adverse events), mean differences for continuous outcomes (procedural time, costs, total/targeted biopsies), and their 95% confidence intervals (CIs) using a random-effects model. Subgroup analyses included technique compared with chromoendoscopy, type of disease, and type of dye. We estimated sensitivity and specificity of the techniques with reference to histology. RESULTS: We identified 10 randomized trials (n = 1500 participants). There was a higher likelihood of detecting patients with dysplasia with chromoendoscopy compared with other techniques (RR, 1.37; 95% CI, 1.04-1.79). Subgroup analyses confirmed this effect only if chromoendoscopy was compared with standard-definition white-light endoscopy (RR, 2.12; 95% CI, 1.15-3.91). Chromoendoscopy required a significantly longer procedural time compared with other techniques (mean difference, 8.91 min; 95% CI, 1.37-16.45). There was no difference in the likelihood of detecting dysplastic subtypes and dysplasia by targeted biopsies between groups. Test sensitivity and specificity were similar between groups. CONCLUSIONS: In surveillance of inflammatory bowel diseases, chromoendoscopy identifies more patients with dysplasia only when compared with standard-definition white-light endoscopy. It is associated with longer procedural time with no direct evidence of effect on preventing all-cause/cancer-specific mortality or time to interval cancer.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Iannone A, Ruospo M, Wong G, et al. Chromoendoscopy for Surveillance in Ulcerative Colitis and Crohn's Disease: A Systematic Review of Randomized Trials. Clin Gastroenterol Hepatol. 2016. PMID: 27890853. doi:10.1016/j.cgh.2016.11.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。